Cyclophosphamide therapy of severe lupus nephritis.
Appel
G B
GB
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
D000328:Adult; D044383:Black People; D018890:Chemoprevention; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000503:physiopathology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D015996:Survival Rate; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide